Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The Platelet 47 kDa type III collagen receptor, often referred to as p47, is a non-integrin membrane protein that specifically mediates the interaction between platelets and type III collagen (Chiang et al., 1993). This receptor is distinct from other major collagen receptors like GPVI and integrin alpha2beta1, and it plays a crucial role in the initial stages of platelet adhesion and activation upon vascular injury (Chiang et al., 2002). Research has characterized this 47 kDa protein as a specific receptor for type III collagen, which is abundant in the subendothelial matrix and triggers intracellular signaling pathways, including protein tyrosine phosphorylation, leading to platelet aggregation and thrombus formation (Chiang et al., 2002). Some evidence suggests that this receptor may be identical or closely related to Heat Shock Protein 47 (HSP47), a collagen-specific chaperone that is also expressed on the platelet surface and promotes adhesion (Sasikumar et al., 2018). Experimental inhibitors, such as the small molecule Col003 and specific sequence-derived peptides, have demonstrated the ability to block type III collagen-induced platelet activation in vitro and in animal models (Ito et al., 2017; Chiang et al., 2002). Consequently, the receptor is considered a potential therapeutic target for the development of selective antithrombotic drugs that may offer a lower bleeding risk than conventional antiplatelet agents.
Inhibition of platelet adhesion and aggregation by blocking the interaction between the receptor and type III collagen.
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Platelet 47 kDa type III collagen receptor (p47).